PARP2 and breast carcinoma: The mouse experimental breast cancer model showed that coordinated double co-silencing of PARP1-/- and PARP2-/- is sufficient for complete impairing of TILs, which was not observed in the tumors with functionally activated PARP1 and PARP2 proteins [44].